CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Development of novel immuno-oncology drug products
3.3 Key findings
3.3.1 Top impacting factors
3.3.2 Top investment pockets
3.3.3 Top winning strategies
3.4 Government regulations
3.4.1 Regulations in Middle East
3.5 Reimbursement scenario
3.5.1 Reimbursement in Middle East
3.6 Drivers
3.6.1 Rising incidence and prevalence of various cancer types
3.6.2 Growing importance of biological and targeted drug therapies
3.6.3 Increasing funding and aid from public and private sector
3.7 Restraints
3.7.1 High cost of drug development and threat of failure
3.7.2 Adverse effects of cancer drug therapy
3.8 Opportunities
3.8.1 Advancement of anti-cancer drugs research
3.8.2 Healthcare and medical awareness
CHAPTER 4 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES,2014-2021
4.1 Chemotherapy
4.1.1 Market size and forecast
4.2 Targeted therapy
4.2.1 Market size and forecast
4.3 Immunotherapy (biologics therapy)
4.3.1 Market size and forecast
4.4 Hormonal therapy
4.4.1 Market size and forecast
4.5 Others
4.5.1 Market size and forecast
CHAPTER 5 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY CANCER TYPES,2014-2021
5.1 Blood cancer
5.1.1 Market size and forecast
5.2 Breast cancer
5.2.1 Market size and forecast
5.3 Gastrointestinal cancer
5.3.1 Market size and forecast
5.4 Prostate cancer
5.4.1 Market size and forecast
5.5 Respiratory/lung cancer
5.5.1 Market size and forecast
5.6 Skin cancer
5.6.1 Market size and forecast
5.7 Other cancers
5.7.1 Trends in treatment of other cancer types
5.7.2 Market size and forecast
CHAPTER 6 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY COUNTRIES,2014-2021
6.1 Brazil
6.1.1 Market size and forecast
6.2 Argentina
6.2.1 Market size and forecast
6.3 Nigeria
6.3.1 Market size and forecast
6.4 South Africa
6.4.1 Market size and forecast
6.5 Iraq
6.5.1 Market size and forecast
6.6 Iran
6.6.1 Market size and forecast
6.7 Algeria
6.7.1 Market size and forecast
6.8 Saudi Arabia
6.8.1 Market size and forecast
6.9 Egypt
6.9.1 Market size and forecast
6.10 Other LAMEA countries
6.10.1 Market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1 Amgen Inc.
7.1.1 Company overview
7.1.2 Business performance
7.1.3 Operating business segment overview
7.1.4 Key strategies and development
7.1.5 SWOT analysis
7.2 AstraZeneca PLC.
7.2.1 Company overview
7.2.2 Business performance
7.2.3 Key strategies and development
7.2.4 SWOT analysis and strategic conclusions
7.3 Roche Diagnostics
7.3.1 Company overview
7.3.2 Operating business segment overview
7.3.3 Business performance
7.3.4 Key strategies moves and development
7.3.5 SWOT analysis
7.4 GlaxoSmithKline PLC
7.4.1 Company overview
7.4.2 Operating business segment overview
7.4.3 Business performance
7.4.4 Key strategies move and development
7.4.5 SWOT Analysis
7.5 Merck & Company
7.5.1 Company overview
7.5.2 Operating business segment overview
7.5.3 Business performance
7.5.4 Key strategies move and development
7.5.5 SWOT analysis
7.6 Novartis AG
7.6.1 Company overview
7.6.2 Operating business segment overview
7.6.3 Business performance
7.6.4 Key strategies move and development
7.6.5 SWOT analysis
7.7 AbbVie Inc.
7.7.1 Company overview
7.7.2 Business performance
7.7.3 Strategic moves and developments
7.7.4 SWOT analysis
7.8 Sanofi
7.8.1 Company overview
7.8.2 Operating business segment overview
7.8.3 Business performance
7.8.4 Key strategies move and development
7.8.5 SWOT analysis
7.9 EIMC United Pharmaceuticals (EUP)
7.9.1 Company overview
7.9.2 Operating business segment overview
7.9.3 Key strategies move and development
7.9.4 SWOT analysis
7.10 Actavis plc
7.10.1 Company overview
7.10.2 Operating business segment overview
7.10.3 Business performance
7.10.4 Key strategies move and development
7.10.5 SWOT analysis